Neoleukin Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference
07 August 2019 - 2:00PM
Neoleukin Therapeutics, Inc. (“Neoleukin”), a biopharmaceutical
company utilizing sophisticated computational methods to design de
novo protein therapeutics, and Aquinox Pharmaceuticals, Inc.
(“Aquinox”) (NASDAQ:AQXP), today announced that Jonathan G.
Drachman, M.D., CEO, of Neoleukin, will present a corporate
overview at the Canaccord Genuity 39th Annual Growth Conference in
New York, NY on Thursday, August 8th, 2019 at 3:00 p.m. Eastern.
A webcast of the presentation, including slides, will be
available at http://wsw.com/webcast/canaccord35/nlt/.
Neoleukin and Aquinox Merger
AnnouncementOn August 6, 2019, Neoleukin Therapeutics and
Aquinox announced that the two companies entered into a definitive
merger agreement under which Aquinox agreed to the acquisition of
Neoleukin. In connection with the merger, Aquinox will be renamed
as Neoleukin Therapeutics, Inc. and is expected to trade on the
Nasdaq under the new ticker symbol NLTX at the time of closing, on
or about August 8th, 2019, subject to customary legal and
regulatory clearances and procedures.
About Neoleukin Therapeutics,
Inc.Neoleukin is a biopharmaceutical company creating next
generation immunotherapies using de novo protein design
technology. Neoleukin uses sophisticated computational
methods to design proteins that demonstrate specific pharmaceutical
properties that provide potentially superior therapeutic benefit
over native proteins. Neoleukin’s lead product candidate,
NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate
alpha receptor binding. For more information, please visit the
Neoleukin website: www.neoleukin.com.
Cautionary Note on Forward-Looking
Statements Certain of the statements made in this press
release are forward looking, including those relating to the
benefits of the merger, future management of the combined company,
Neoleukin’s business, the strategy of the combined company, future
operations, advancement of its product candidates and product
pipeline, clinical development of the combined company’s product
candidates, including expectations regarding timing of regulatory
submissions and initiation of clinical trials, regulatory
requirements for initiation of clinical trials and registration of
product candidates, the sufficiency of its cash resources and other
statements containing the words “anticipate,” “believe,” “expect,”
“may,” “plan,” “project,” “potential,” “will,” “would,” “could,”
“continue,” and similar expressions. These statements are subject
to risks and uncertainties that could cause actual results and
events to differ materially from those anticipated, including, but
not limited to, risks and uncertainties related to: whether results
of early clinical trials or preclinical studies will be indicative
of the results of future trials, the adequacy of any clinical
models, uncertainties associated with regulatory review of clinical
trials; our ability to identify or acquire additional clinical
candidates, our ability to obtain and maintain regulatory approval
for any product candidates and the potential safety, efficacy or
clinical utility of or any product candidates, and other factors
discussed in the “Risk Factors” section of the Aquinox’s report on
Form 10-Q for the quarter ended June 30, 2019 as filed with the
Securities and Exchange Commission. Actual results or developments
may differ materially from those projected or implied in these
forward-looking statements. More information about the risks and
uncertainties faced by Aquinox is contained in the company’s
Quarterly Report on Form 10-Q for the quarter ended June 30,
2019, and subsequent reports, filed with the Securities and
Exchange Commission. Aquinox disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contacts:
MediaJulie
Rathbun206-769-9219jrathbun@neoleukin.com
InvestorsSolebury TroutBrian
Korb646-378-2923bkorb@troutgroup.com
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Aquinox Pharmaceuticals (NASDAQ:AQXP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024